An interventional study of Scaling and Root Planing in Periodontal Diseases, sponsored by Esra İlkerli Şençağlı. Recruiting at 1 site in Cyprus. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Esra İlkerli Şençağlı · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to investigate the prevalence and severity of periodontal diseases among university students from three different national backgrounds (Iranian, Sudanese, and Turkish) and to evaluate their response to periodontal treatment.
A total of 348 students will be included in the study, comprising 116 Iranian, 116 Sudanese, and 116 Turkish students. Periodontal health assessments will be performed, and all participants will receive periodontal treatment according to the study protocol.
The study will compare periodontal disease prevalence and severity among the three groups and evaluate changes in periodontal health following treatment.
This study investigates the prevalence and severity of periodontal diseases among university students from three different national backgrounds and evaluates their response to periodontal treatment.
A total of 348 university students will be included in the study, consisting of 116 students of Iranian origin, 116 students of Sudanese origin, and 116 students of Turkish origin.
At baseline, all participants will undergo a comprehensive periodontal examination to assess their periodontal health status. Clinical periodontal parameters will be recorded using standardized periodontal assessment methods.
All participants will receive periodontal treatment according to the study protocol. The treatment includes professional scaling and oral hygiene instruction. Root planing will be performed when clinically indicated, depending on the periodontal condition of each participant.
Three weeks after treatment, participants will undergo a follow-up periodontal examination. Clinical periodontal parameters will be reassessed to evaluate changes in periodontal health and treatment response.
The findings will be compared among the three student groups to investigate differences in periodontal disease prevalence, severity, and response to treatment.
The study aims to provide information about periodontal health differences among students from different national backgrounds and their response to periodontal treatment.
871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.
This study's planned enrollment of 348 is above the median of 45 across 559 interventional studies indexed under Periodontal Diseases.
Browse Periodontal Diseases studies →This is the only study on the registry with Esra İlkerli Şençağlı as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All 348 participants will receive periodontal treatment according to their individual clinical needs. Treatment will include scaling and root planing when clinically indicated. Participants will be evaluated at baseline and reassessed three weeks after treatment to assess periodontal treatment outcomes.
Procedure: Scaling and Root Planing
Participants will receive non-surgical periodontal treatment according to their individual clinical needs. The treatment will include scaling and root planing where clinically indicated. The procedure will be performed based on baseline periodontal examination findings. All participants will be reassessed three weeks after treatment to evaluate changes in periodontal clinical parameters, including plaque index, gingival index, probing pocket depth, clinical attachment level, and tooth mobility.
Change in Probing Pocket Depth (PPD)
Change in mean probing pocket depth (PPD) from baseline to the three-week follow-up after periodontal treatment. Measurements will be compared among Iranian, Sudanese, and Turkish student groups.
Time frame: Baseline and 3 weeks after periodontal treatment
Change in Plaque Index (PI) Assessed Using the Silness and Löe Plaque Index
Dental plaque will be assessed clinically using the Silness and Löe Plaque Index (1964). Plaque accumulation will be scored on a scale ranging from 0 to 3: 0: No plaque. 1. A film of plaque adhering to the free gingival margin and adjacent tooth area, detectable only by running a probe across the tooth surface. 2. Moderate accumulation of soft deposits within the gingival pocket or on the tooth and gingival margin, visible to the naked eye. 3. Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin. The minimum score is 0 and the maximum score is 3. Higher scores indicate greater plaque accumulation and a worse oral hygiene outcome. Measurements will be performed at baseline and 3 weeks after periodontal treatment.
Time frame: Baseline and 3 weeks
Change in Gingival Index (GI) Assessed Using the Löe and Silness Gingival Index
Gingival inflammation will be assessed clinically using the Löe and Silness Gingival Index (1963). Gingival tissues will be scored on a scale ranging from 0 to 3: 0: Normal gingiva, no inflammation. 1. Mild inflammation, slight color change and slight edema, with no bleeding on probing. 2. Moderate inflammation, redness, edema, and glazing, with bleeding on probing. 3. Severe inflammation, marked redness and edema, ulceration, and a tendency to spontaneous bleeding. The minimum score is 0 and the maximum score is 3. Higher scores indicate more severe gingival inflammation and a worse periodontal outcome. Measurements will be performed at baseline and 3 weeks after periodontal treatment.
Time frame: Baseline and 3 weeks
Change in Clinical Attachment Level (CAL)
Time frame: Baseline and 3 weeks
Change in Tooth Mobility Assessed Using the Miller Mobility Index
Tooth mobility will be assessed clinically using the Miller Mobility Index. Each examined tooth will be evaluated for horizontal and vertical mobility using two rigid instrument handles. Mobility will be classified as follows: Grade 0: Physiologic tooth mobility. Grade 1: Slight horizontal mobility of less than 1 mm. Grade 2: Horizontal mobility of more than 1 mm without vertical mobility. Grade 3: Severe horizontal mobility accompanied by vertical mobility. Higher grades indicate greater tooth mobility and a worse periodontal outcome. Tooth mobility will be assessed at baseline and 3 weeks after periodontal treatment.
Time frame: Baseline and 3 weeks
Change in Bleeding on Probing (BOP) Percentage
Bleeding on probing (BOP) will be assessed as a clinical indicator of gingival inflammation using a periodontal probe. The periodontal probe will be gently inserted into the gingival sulcus to evaluate the presence or absence of bleeding following probing. Each periodontal site will be recorded using a dichotomous scoring system: Score 0: Absence of bleeding on probing. Score 1: Presence of bleeding on probing. The BOP percentage will be calculated by dividing the total number of bleeding-positive sites by the total number of examined periodontal sites and multiplying by 100. BOP (%) = (Number of bleeding-positive sites / Total number of examined sites) × 100. The minimum value is 0% and the maximum value is 100%. Higher percentages indicate a greater proportion of bleeding sites and more pronounced gingival inflammation.
Time frame: Baseline and 3 weeks
Prevalence and Severity of Periodontal Disease
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.
Of 314 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 36 months is above that.
Counting every sponsor, half of 333 studies reached it within 13 months; a quarter within 8 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.